1 414-918-9890

2022 China Cancer Immunotherapy Workshop

September 2-3, 2022 (Beijing, China)
September 1-2, 2022 (United States)

In person: Beijing, China
Virtual: United States and Europe

Organized by CAHON, CCFDIE, and CDE at NMPA and Tsinghua University College of Medicine with participation from top Immunotherapy experts from academia, regulatory agencies (EMA, FDA and NMPA) and biopharma industry.

CAHON is pleased to present the 2022 China Cancer Immunotherapy Workshop (in-person in Beijing, China). Since 2015, CAHON has partnered with the China National Medical Products Administration (NMPA) and the Tsinghua University College of Medicine to organize this important event. This workshop hosts speakers from these major regulatory agencies, the US FDA, European Medicines Agency (EMA) and additional experts in the immuno-oncology field. The meeting will take place in-person in Beijing, China and virtually for participants outside of China.

Registration

CAHON Members

  • CAHON Members residing in China must contact the Executive Office at info@cahon.org to register for the event.
  • CAHON Members (current in dues) residing outside of China will receive complimentary registration.

Non-members

  • Non-Members residing outside of China may register for the event for a fee of $100.00 USD.
  • There are limited online registration slots available for OVERSEAS NON-CAHON members.


You must register by Friday, September 2nd before 10:00pm Eastern time

Program Agenda

The program features world-renowned experts in the immuno-oncology field. Please view the program agenda below:

To download the program in English, click here.
To download the program in Chinese, click here.

 

2022 China Cancer Immunotherapy Workshop Sponsors

Diamond Level

                            

 

Cookie Notice

This website uses cookies to deliver to you the best experience possible on the CAHON website. By continuing to use this site, you are providing to us your consent to ensure you receive such an experience. View our privacy policy to learn more.

Accept